About Homeobox protein Nkx-2.1
Homeobox protein Nkx-2.1 (NKX2-1) is a protein
from Homo sapiens identified by UniProt accession
P43699, 371 residues long.
MolForge cross-references it against 0 known binders and
474 disease associations.
Target properties
| Protein name | Homeobox protein Nkx-2.1 |
|---|
| UniProt accession | P43699 |
|---|
| Gene | NKX2-1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 371 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (474)
Diseases linked to this target (Open Targets).
- brain-lung-thyroid syndrome · score 0.81
- Benign familial chorea · score 0.81
- chorea · score 0.75
- genetic disorder · score 0.52
- neurodegenerative disease · score 0.51
- papillary thyroid carcinoma · score 0.50
- thyroid cancer, nonmedullary, 1 · score 0.47
- body height · score 0.43
- age at menarche · score 0.41
- non-small cell lung carcinoma · score 0.39
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P43699-F1 | alphafold | PREDICTED | 56.30 | — |
Amino-acid sequence (371 residues)
MSMSPKHTTP FSVSDILSPL EESYKKVGME GGGLGAPLAA YRQGQAAPPT AAMQQHAVGH HGAVTAAYHM TAAGVPQLSH SAVGGYCNGN LGNMSELPPY QDTMRNSASG PGWYGANPDP RFPAISRFMG PASGMNMSGM GGLGSLGDVS KNMAPLPSAP RRKRRVLFSQ AQVYELERRF KQQKYLSAPE REHLASMIHL TPTQVKIWFQ NHRYKMKRQA KDKAAQQQLQ QDSGGGGGGG GTGCPQQQQA QQQSPRRVAV PVLVKDGKPC QAGAPAPGAA SLQGHAQQQA QHQAQAAQAA AAAISVGSGG AGLGAHPGHQ PGSAGQSPDL AHHAASPAAL QGQVSSLSHL NSSGSDYGTM SCSTLLYGRT W
Explore Homeobox protein Nkx-2.1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets